Toxic serotonin syndrome or neuroleptic malignant syndrome?
Administration of medications which affect brain dopamine and serotonin levels are occasionally associated with neurotoxic behavioral and autonomic syndromes, variously described as the neuroleptic malignant (NMS) and the toxic serotonin (TSS) syndromes. Based on concepts of the presumed brain mechanisms of action of the drugs, different corrective interventions have been recommended. We describe a case of neurotoxic syndrome with characteristics indistinguishable from NMS in which the offending agents are those which affect the serotonin and not the dopamine systems. The patient recovered with lorazepam and electroconvulsive therapy (ECT). We argue that NMS and TSS are examples of a non-specific generalized neurotoxic syndrome, and not specific syndromes: and that these are subtypes of catatonia. Patients today should be treated with benzodiazepines, and if these fail, with ECT, interventions which are effective in relieving catatonia.
Fink
M
M
Department of Psychiatry and Behavioral Sciences, School of Medicine, SUNY at Stony Brook, St. James, USA.
D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects; D002493:Central Nervous System Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy; D004565:Electroconvulsive Therapy; D005260:Female; D006801:Humans; D008140:Lorazepam / Q000627:therapeutic use; D008875:Middle Aged; D009459:Neuroleptic Malignant Syndrome / Q000175:diagnosis* / Q000188:drug therapy / Q000628:therapy; D009661:Nortriptyline / Q000009:adverse effects
D000929:Antidepressive Agents, Tricyclic; D009661:Nortriptyline; D008140:Lorazepam